A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood
Phase 1
Completed
NCT06041438
| Condition | Healthy |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Boehringer Ingelheim |
|---|
| Status | Completed |
|---|
| Enrollment | 14 participants |
|---|
| Interventions | BI 1584862, Itraconazole |
|---|
| Start date | Sep 29, 2023 |
|---|
| Completion date | Nov 10, 2023 |
|---|
| Results posted | Jun 3, 2026 |
|---|
Summary
The main objective of this trial is to investigate the effect on the exposure of BI 1584862 in plasma when given as single dose together with multiple doses of itraconazole (Test, T) as compared to BI 1584862 when given alone as oral single dose (Reference, R).
Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Within 3 to 4 h before and up to 3 days after BI 1584862 administration. · hour*nanomole/Liter
| BI 1584862 (R) | 999.27 ± NA hour*nanomole/Liter |
|---|
| BI 1584862 + Itraconazole (T) | 7981.53 ± NA hour*nanomole/Liter |
|---|
| Ratio of adjusted geometric means [%] | 798.74 (95% CI 688.62–926.46) |
|---|
Maximum Measured Concentration of BI 1584862 in Plasma (Cmax)
Within 3 to 4 h before and up to 3 days after BI 1584862 administration. · nanomole/Liter
| BI 1584862 (R) | 408.11 ± NA nanomole/Liter |
|---|
| BI 1584862 + Itraconazole (T) | 801.07 ± NA nanomole/Liter |
|---|
| Ratio of adjusted geometric means [%] | 196.29 (95% CI 174.54–220.75) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.